Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Removal of US Securities Law Restrictions on Ordinary Shares

May 5, 2020
Download  full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence  in vitro  diagnostics for kidney disease, announces  that, following legal advice, it has taken the decision to remove the offering restrictions imposed by US securities law

Provider network agreement for KidneyIntelX™

April 15, 2020
Download  full announcement Agreement with Three Rivers Provider Network, the fastest growing US proprietary provider network KidneyIntelX   risk assessment testing now available to Three Rivers members and clients Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial

Medicare provider number

April 1, 2020
Keyword Company EPIC/TIDM SEDOL/ISIN News     Price Announcements Fundamentals News Article RSS Renalytix AI PLC (RENX) Add to Alerts list    Print         Mail a friend Wednesday 01 April, 2020 Renalytix AI PLC   RNS Number : 3212I Renalytix AI PLC 01 April 2020     Renalytix AI plc

Presentation of KidneyIntelX™ Health Economics Data

March 27, 2020
Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence  in vitro  diagnostics for kidney disease, announces  that further to  RNS Reach 2937H on 24 March 2020,  Boston Healthcare Associates has presented data on  KidneyIntelX™, the Company’s AI-enabled in
Displaying 441 - 450 of 527